The Approach of Thromboelastography in the Monitoring of New Synthetic Antithrombotic Agents, GL-522 and GL-2021

• References

• 1 Thromboelastograph^® Operations Manual and CTEG User's Guide. Haemoscope Corporation; 1990: 9
• 2 Caprini JA, Tuckermam L, Cohen E, Vagher JP, Lipp V. The identification of accelerated coagulability. Thromb Res 9: 167-180 1976;
• 3 Von Kaulla KN. Continuous automatic recording of fibrin formation and fibrinolysis: A valuable tool for coagulation research. J Lab Clin Med 49: 304-312 1957;
• 4 De Nicola P, Mazzetti GM. Evaluation of thromboelastography. Am J Clin Pathol 25: 447-452 1955;
• 5 Astrup T, Egerbald K. Thromboelastographic patterns produced by fibrinolytic agents incorporated in fibrin. Am J Physiol 209: 84-94 1965;
• 6 Ramstack JM, Zuckerman L, Mockerds LF, Caprini JA, Vagher JP. Effect of platelet count and hematocrit on the coagulability of heparinized blood. Res Commun Chem Pathol Pharmacol 21: 327-342 1978;
• 7 Howland WS, Castro EB, Fortner JB, Gould P. Hypercoagulability, thromboelastographic monitoring during extensive hepatic surgery. Arch Surg 108: 605-608 1974;
• 8 Raby C. Control of heparin therapy by thromboelastography. In: Kakkar VV, Thomas DP, (Eds) Heparin, Chemistry and Clinical Usage. Academic Press; London: 1976: 211-218
• 9 Raby C. Heparinotherapic controllee. Presse Med 74 1976; 1526
• 10 Hume M. The relation of “hypercoagulability” to thrombosis. Surg Sci 2: 133-158 1966;
• 11 Collins GJ, Aher OJ, Rich NM, Anderson CA. Detection and management of hypercoagulability. Am J Surg 132: 767-770 1976;
• 12 De Nicole P. Thromboelastography. Springfield, IL; Charles C Thomas: 1957
• 13 Merskey C. Pathogenesis and treatment of altered blood coagulability in patients with malignant tumors. Ann NY Acad Sci 230: 289-296 1974;
• 14 Gollub S, Schaefer C. Structural alteration in canine fibrin produced by colloid plasma expanders. Surg Gynecol Obstet 127: 783-793 1968;
• 15 Jeske W, Lojewski B, Fareed J. Biochemical and pharmacologic studies on a novel polysulfonated oral antithrombotic agent (GL-522-Y-1). Blood 80 (Suppl 1) 1992; 322a